Evidence map›Paper›PMID 42385115›Full record

ArticleNeurology2026

Putamen Dopamine Synthesis, Vesicular Storage, and Metabolism in Patients With Parkinson Disease.

David S Goldstein

Abstract read
PubMed Publisher
In one paragraph

Article in Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

David S GoldsteinFrom the Clinical Neurosciences Program, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-5709-9940

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesPutamen dopamine depletion characterizes Parkinson disease (PD). Intraneuronal processes determining dopamine stores have not been systematically examined. This study explored relative contributions of dopamine synthesis, storage, and metabolism to control-PD differences.

methodsWe updated an intramural tabulation from 2002 to 2024 of postmortem putamen tissue contents of reactants, including the autotoxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL), from patients with PD and controls. Based on computational models applying first-order kinetics and equilibrium equations, we then compared estimated rates of dopamine synthesis through tyrosine hydroxylase (TH), L-aromatic-amino-acid decarboxylase, vesicular active uptake and passive leakage, exocytotic release and reuptake, and other intraneuronal processes. Results from the modeling were compared with those from in vivo

resultsPostmortem data were analyzed from 13 patients with PD (median age 77 years, range 73-85 years) and 20 controls (median age 77 years, range 35-91 years). There was approximately a 98% decrease in putamen tissue dopamine in PD, and the concentration ratio of DOPAL/dopamine (DA) was approximately 9 times that of control. Applying the simplest kinetic model, vesicular sequestration was estimated to be decreased by 98.5% (0.073 vs 4.91 nmol/minute). Approximately 3-fold greater in vivo "washout" of putamen DISCUSSION: Convergent quantitative evidence points to a substantial vesicular storage defect in residual dopaminergic terminals in PD. This finding challenges the sufficiency of nigrostriatal dopaminergic denervation alone to account for the biochemical phenotype of PD and highlights vesicular dopamine handling as a critical determinant of putamen dopamine deficiency. The reaction rate estimates were drawn from published point values rather than fitted to an experimental data set, and so conventional goodness-of-fit regression statistics were not conducted. Because of the assumption of steady-state conditions for calculating reaction rates based on equilibrium equations, the model does not address the dynamics of disease pathogenesis over years but does provide a platform for further extension to disease progression. BRIEF SUMMARY: We estimated rates of reactions involved with the synthesis, storage, release, reuptake, and metabolism of dopamine in the putamen in PD and found that the main intraneuronal functional abnormality separating PD from controls was attenuated vesicular sequestration, implicating decreased vesicular uptake through the vesicular monoamine transporter and increased vesicular leakiness as key determinants of putamen dopamine deficiency in PD.

Indexed as

DopamineParkinson DiseasePutamenSynaptic Vesicles3,4-Dihydroxyphenylacetic AcidAgedAged, 80 and overAromatic-L-Amino-Acid DecarboxylasesDopaminergic ImagingFemaleHumansMalePositron-Emission TomographyTyrosine 3-Monooxygenase3,4-dihydroxyphenylacetaldehyde3,4-Dihydroxyphenylacetic AcidAromatic-L-Amino-Acid DecarboxylasesDopamineTyrosine 3-Monooxygenase

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.